Prima BioMed Ltd (PBMD.OQ)

PBMD.OQ

About

Prima BioMed Ltd is a biotechnology company is engaged in the development and commercialization of medical therapies with a focus on oncology. Its product candidates in development include Cvac, an autologous dendritic cell vaccine for ovarian cancer, monoclonal antibodies for multiple tumour types, and an oral formulation for... (more)

Buy/Sell

» Analyst Consensus

Overall

Beta:	3.84
Market Cap (Mil.):	$73.16
Shares Outstanding (Mil.):	1,143.15
Dividend:	--
Yield (%):	--

Financials

	PBMD.OQ	Industry	Sector
P/E (TTM):	--	39.38	31.28
EPS (TTM):	-0.02	--	--
ROI:	-48.45	2.42	18.90
ROE:	-48.65	3.64	19.80

Latest News about PBMD.OQ

» More PBMD.OQ News

Earnings vs. Estimates

Analyst Research Reports

Report Title	Price
Thomson Reuters Stock Report - PRIMA BIOMED LIMITED (PRR-AU) Provider: Thomson Reuters Stock Report	$25.00 Buy
Wright Investors Service Comprehensive Report for Prima Biomed Limited Provider: Wright Reports	$449.00 Buy
Prima BioMed Ltd: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. Provider: Reuters Investment Profile	$20.00 Buy
Prima BioMed Limited (PRR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Provider: GlobalData	$250.00 Buy
Prima BioMed Limited (PRR) - Financial Analysis Review Provider: GlobalData	$125.00 Buy

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

» More Analyst Research

Related Topics:

Edition:

U.S.
- Arabic
- Argentina
- Brazil
- Canada
- China
- France
- Germany
- India
- Italy
- Japan
- Latin America
- Mexico
- Russia
- Spain
- United Kingdom

Back to top

Reuters.com

Legal

Support & Contact

Connect with Reuters

About

Our Flagship financial information platform incorporating Reuters Insider

An ultra-low latency infrastructure for electronic trading and data distribution

A connected approach to governance, risk and compliance

Our next generation legal research platform

Our global tax workstation

Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.

NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.